Rising Prevalence of Certain Diseases Expenditure Drive the Demand for Omega-3 Ingredients for Pharmaceuticals Market

The ageing population and the high prevalence of cardiovascular diseases are expected to drive market growth. According to the World Health Organization, cardiovascular diseases (CVDs) are the leading cause of death worldwide, claiming an estimated 17.9 million lives each year. Heart attacks and strokes account for more than four out of every five CVD deaths, with one-third of these deaths occurring in people under the age of 70. People's attention has been drawn to their health and dietary habits as a result of these alarming statistics. Consumers are spending more money on dietary supplements and incorporating omega-3 ingredients into their diets to build strong immunity and support heart and brain health, which is expected to drive demand for omega-3 ingredient products in the coming years.

Access full Report @https://www.databridgemarketresearch.com/reports/global-omega-3-ingredients-for-pharmaceuticals-market

Data Bridge Market Research analyses that the omega-3 ingredients for pharmaceuticals market is expected to grow at a CAGR of 11.0% in the forecast period of 2020 to 2027 and is expected to reach USD 1,195.34 thousand by 2027.

Omega-3 Ingredients for Pharmaceuticals Market

Immense growth in concentrated forms of algal omega-3 ingredients is expected to drive the market's growth rate

New ultra-high concentrated omega-3 ingredients provide numerous benefits to consumers willing to pay a higher premium price for high-end products. Suppliers are investing in the production of high concentrated algal omega-3 products, expecting increased demand to drive the sales. The market for concentrates has also been growing, as more consumers become aware of the benefits of algal omega-3 and seek the benefits of higher doses. Given the existing opportunities in the market studied, major companies involved in omega-3 manufacturing have begun to strategically capitalize on the existing business expansion opportunity.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2020 to 2027

Base Year

2019

Historic Years

2018 (Customizable to 2012 - 2017)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Source (Marine and Plant), Type (Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA), Alpha-Linolenic Acid (ALA)), Forms (Liquid and Dry), Therapeutic Areas (Cardiovascular Diseases, Autoimmune Diseases, Bone & Joint Disorders, Neurological Disorders, Ophthalmic Disorders, Skin Health, Cancer, Others), Population Type (Adults and Children), Distribution Channel (Direct and Indirect)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Avestia Pharma (India), Novasep (France), AbbVie Inc. (U.S.), KD Pharma Group (Japan), BASF SE (U.S.), Corbion (Netherlands), DSM (Netherlands), AstraZeneca (U.K.), GlaxoSmithKline plc. (U.K.), Fresenius Kabi AG (Germany), Croda International Plc (U.S.), AMARIN CORPORATION (Ireland), ANI Pharmaceuticals, Inc. (U.S.), Epax (Norway), Strides Pharma Science Limited (India), Pharma Marine AS (Norway), KinOmega Biopharm Inc. (China), Camber Pharmaceuticals, Inc. (U.S.)

Data Points Covered in the Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

Global omega-3 ingredients for pharmaceuticals market is categorized into six notable segments which are based on the basis of source, type, forms, therapeutic areas, population type and distribution channel.

  • On the basis of source, the omega-3 ingredients for pharmaceuticals market is segmented into marine and plant.

In 2020, marine segment is expected to dominate the omega-3 ingredients for pharmaceuticals market

Marine segment is expected to dominate the omega-3 ingredients for pharmaceuticals market due to presence of higher proportion of good content omega-3 components in marine fish.

  • On the basis of type, the omega-3 ingredients for pharmaceuticals market are segmented into docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), alpha-linolenic acid (ALA). In 2020, docosahexaenoic acid (DHA) segment is dominating the omega-3 ingredients for pharmaceuticals market due to the critical role in brain expansion, and regulation of heart disease.
  • On the basis of forms, the omega-3 ingredients for pharmaceuticals market are segmented into dry and liquid.

In 2020, the liquid segment is dominating the omega-3 ingredients for pharmaceuticals market

The liquid segment is dominating the omega-3 ingredients for pharmaceuticals market as most of the Omega-3 ingredients are obtained in liquid form. Furthermore, liquid form is preferred over other forms for a variety of end user applications in the pharmaceutical industry.

  • On the basis of therapeutic areas, the omega-3 ingredients for pharmaceuticals market are segmented into ophthalmic disorders, neurological disorders, cardiovascular diseases, autoimmune diseases, cancer, bone & joint disorders, skin health and others. In 2020, cardiovascular diseases segment is dominating the omega-3 ingredients for pharmaceuticals market because of the applications of omega-3 fatty acids in lowering triglycerides, slightly lowering blood pressure, lowering the risk of strokes, lowering blood clotting, and lowering irregular heartbeats.
  • On the basis of population type, the omega-3 ingredients for pharmaceuticals market are segmented into children and adults. In 2020, adults segment is dominating the omega-3 ingredients for pharmaceuticals market because the major application of Omega-3 ingredients in pharmaceutical applications is cardiovascular diseases. These diseases are predominantly prevalent in adults as compared to children.
  • On the basis of distribution channel, the omega-3 ingredients for pharmaceuticals market are segmented into direct and indirect. In 2020, direct segment is dominating the omega-3 ingredients for pharmaceuticals market as it is the primary source of procurement by pharmaceutical companies.

Major Players

Data Bridge Market Research recognizes the following companies as the major omega-3 ingredients for pharmaceuticals market players in omega-3 ingredients for pharmaceuticals market are Avestia Pharma (India), Novasep (France), AbbVie Inc. (U.S.), KD Pharma Group (Japan), BASF SE (U.S.), Corbion (Netherlands), DSM (Netherlands), AstraZeneca (U.K.), GlaxoSmithKline plc. (U.K.), Fresenius Kabi AG (Germany), Croda International Plc (U.S.), AMARIN CORPORATION (Ireland), ANI Pharmaceuticals, Inc. (U.S.), Epax (Norway), Strides Pharma Science Limited (India), Pharma Marine AS (Norway), KinOmega Biopharm Inc. (China), Camber Pharmaceuticals, Inc. (U.S.)

Omega-3 Ingredients for Pharmaceuticals Market

Market Development

  • In May 2020, DSM launched a plant-based DHA oil product, DHA SF55-O200DS oil extracted from schizochytrium algae. This supplement is used to improve the nutrition of mothers and infants. DSM's new product launch expanded its product portfolio in the nutrition business, increasing demand for its product in the market and resulting in increased revenue in the future.
  • In April 2020, ANI Pharmaceuticals, Inc. launched omega-3-Acid Ethyl Esters Capsules USP to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (greater than or equal to 500mg per dL) (HGT). The company has benefited from expanding its product portfolio and attracting new customers.
  • In May 2019, Croda International Plc and a PhD scholar in research plan collaborated on innovation and development for the Open Innovation Programme. The company's global sales have increased, as has its profit.

Regional Analysis

Geographically, the countries covered in the omega-3 ingredients for pharmaceuticals market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

As per Data Bridge Market Research analysis:

North America is the dominant region in omega-3 ingredients for pharmaceuticals market during the forecast period 2020 - 2027

In 2019, North America dominated the omega-3 ingredients for pharmaceuticals market due to growing usage of pharmaceutical products containing omega-3 ingredients for prevention of cardiovascular disease.

Asia-Pacific is estimated to be the fastest growing region in omega-3 ingredients for pharmaceuticals market the forecast period 2020 - 2027

Asia-Pacific is expected to grow during the forecast period due to rise in consumer demand for plant-based omega-3 products. Germany is dominating the European market owing to growing demand of functional and supplements food.

For more detailed information about the omega-3 ingredients for pharmaceuticals market report, click here – https://www.databridgemarketresearch.com/reports/global-omega-3-ingredients-for-pharmaceuticals-market